During an earnings call Wednesday, Eli Lilly instead blamed it on drug wholesalers cutting inventory of Zepbound and Mounjaro. Wholesalers purchase medicines from manufacturers and sell them to ...

Pharmaceutical company Eli Lilly warning in an open letter on Thursday about the dangers of fake and compounded versions of its diabetes and weight loss medications Mounjaro and Zepbound.

Eli Lilly LLY-0.21%decrease; red down pointing triangle revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio. The drug maker logged ...

Eli Lilly has followed a similar template to that of Novo Nordisk. Mounjaro is Lilly's response to Ozempic, and is used in treating diabetes. Last year was Mounjaro's first full calendar year on ...

Tirzepatide is the active ingredient in Lilly weight-loss drug Zepbound and the diabetes drug Mounjaro. Related Experimental Eli Lilly weight loss drug proves promising for type 2 diabetics Eli ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as supply of both medicines has largely recovered ...